Citing significant, unresolved safety risks, a total lack of robust human clinical efficacy data, and grave concerns over immunogenicity and peptide-related impurities, the FDA officially designated 19 of the most popular therapeutic peptidesexplicitly including BPC-157, TB-500 (Thymosin beta-4 fragment), and injectable GHK-Cuas Category 2 bulk drug substances
[14] In a separate investigation of ulcers, it was reported that wounds exposed to GHK may suggest increased neutrophil countscells essential for the immune responseand a greater density of blood vessels compared to the control group
Roche Lead assets: CT-388/enicepatide
It is not used here as a product claim
The Research Behind It The foundational work on 5-Amino-1MQ came from the Yoon lab at the University of Texas
The rationale is: First course: Addresses the existing senescent cell burden